Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11Gastrointestinal 11Tumor-Agnostic 8Other solid neoplasm 5Genitourinary 5Breast 3Sarcoma 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ARQ 197 × Sarcoma × Clear all
NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
32 enrolled 21 charts
Sarcoma

Neoplasms, Sarcoma

NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Completed
47 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡